XML 64 R50.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Significant Accounting Policies - Additional Information (Detail) - USD ($) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2024 | Nov. 30, 2023 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Banking service obligation | $ 2,500,000 | $ 4,700,000 |  |  |
Musculoskeletal Transplant Foundation ("MTF") [Member] |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Expenditures for other research and development |  |  | $ 300,000 | $ 800,000 |
Maximum [Member] |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Transactional foreign currency gains and (losses), including those generated from intercompany operations |  |  | $ (4,400,000) | $ 1,600,000 | $ (3,300,000)
Maximum [Member] | Musculoskeletal Transplant Foundation ("MTF") [Member] |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Expenditures for other research and development |  |  |  |  | $ 100,000

X
- Definition Banking service obligation + References No definition available. + Details
Name: | ofix_BankingServiceObligation
Namespace Prefix: | ofix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Summary of significant accounting policies. + References No definition available. + Details
Name: | ofix_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, before tax, of realized gain (loss) from foreign currency transaction. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details
Name: | us-gaap_ForeignCurrencyTransactionGainLossRealized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis=ofix_MusculoskeletalTransplantFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |